Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.

Abstract: Early developing stage-specific liver proteins and the genes coding for them that have been isolated and sequenced are provided, and these genes and proteins can be utilized to diagnose and/or treat a wide variety of liver disorders and other ailments. Since the early developing liver proteins of the invention arise during embryogenesis when the liver and other organs are in transition from an undifferentiated state to a differentiated one, these proteins are involved in tissue differentiation and thus can be utilized in methods of diagnosing and treating a variety of liver diseases and other disorders including those relating to oncogenesis and tissue repair. Antibodies recognizing early developing liver proteins and peptides are also provided.

Abstract: The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.

Abstract: Presented are intrinsically fluorescent, self-multimerizing MHC fusion proteins, and complexes assembled therefrom that are capable of detectably labeling antigen-specific T lymphocytes. Also presented are methods for labeling antigen-specific T lymphocytes with the intrinsically fluorescent complexes of the present invention, and methods, particularly flow cytometric methods, for detecting, enumerating, enriching, and depleting antigen specific T lymphocytes so labeled.

Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.

Abstract: The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

Abstract: The present invention relates to cell-regulatory proteins and to nucleotide sequences encoding said proteins wherein the proteins have been found to be potential tumor and/or senescense markers useful for medical diagnostics and additionally having therapeutical potential as well as antiapoptotic properties useful for improving cell viability in cell culture technology. The invention further relates to antibodies directed against the cell-regulatory proteins and to their use in medical diagnostics and therapy. The invention further relates to methods for the manufacture and application of the cell-regulatory proteins and of the corresponding nucleotide sequences.

Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an ?2,3- and an ?2,8-activity. A ?1,4-GalNAc transferase and a ?1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

Abstract: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.

Abstract: The present invention has for its object to provide a DNA sequence capable of regulating the expression of a desired gene specifically in the fruit of a plant, a plasmid containing that DNA sequence as well as a plant cell, plant body and microorganism transformed with the plasmid. One aspect of the present invention is constituted by a fruit-specific expression-regulating unit DNA sequence which comprises a region comprising the base sequence shown under SEQ ID NO:1.

Abstract: The regulatory sequences (i.e., promoter regions, introns and enhancers) associated with the Yarrowia lipolytica gene encoding fructose bis-phospate aldolase (FBA1) have been found to be particularly effective for the expression of heterologus genes in oleaginous yeast. The promoter regions of the invention have been shown to drive high-level expression of genes involved in the production of ?-3 and ?-6 fatty acids.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of diseases associated with expression of acyl CoA cholesterol acyltransferase-2 are provided.

Abstract: Methods for producing ligand arrays, e.g., peptide and nucleic acid arrays, as well as the arrays produced thereby, methods for use of the arrays and kits that include the same are provided. In one embodiment of the subject methods, a substrate having a surface displaying acetate functional groups that produce surface bound hydroxyl functional groups upon hydrolysis is first provided, where the acetate groups are then hydrolyzed to hydroxyl functional groups. In another embodiment of the subject methods, a substrate having a surface displaying alkenyl functional groups is first provided, where the alkenyl functional groups are then converted to carboxylic functional groups. The resultant substrates, optionally after an additional functionalization step, are then contacted with ligands, e.g., via deposition of each different ligand onto a different region of the surface, resulting in covalent attachment of the contacted ligands to the surface.

Abstract: Disclosed is an azaoxa heterocyclic compound represented by the following formula (I): (wherein, each symbol is defined the same as in the specification) and a method for preparing the same. This compound of the present invention is prepared by the reaction of a phenolic compound, an aromatic diamine compound and an aldehyde compound. The azaoxa heterocyclic compound of the present invention can be used as a hardening resin or a hardener for an epoxy resin, polyether and a resin containing active hydrogen atoms, wherein the composition formed by the azaoxa heterocyclic compound and the epoxy resin is useful in the application of laminates, adhesive, semiconductor packaging materials and phenolic resin forming materials.

Abstract: Risperidone is prepared in a high yield by reacting 2,4-difluorophenyl(4-piperidinyl)methanone oxime hydrochloride and 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in an aqueous alkali hydroxide solution having an alkali hydroxide concentration in the range of 20 to 40%.

Abstract: This invention relates to compounds of the formula: wherein: the substituent groups defined by R1, R2 are each independently selected of H, C(?O)R?, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl; each of the R? groups is independently selected from the group consisting of H; OH; NO2; NH2; SH; CN; halogen; ?O; C(?O)H; C(?O)CH3; CO2H; or C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl, each of which, independently, may be substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, nitro, azido; alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, aryloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aminoalkyl, carbocylic aryl having 6 or more carbons, and aralkyl; X2 is OX1 or N(X1)2 wherein each X1 is independently H, C(?O)R? where R? is as defined, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, aryl, alkoxy, heterocyclyl, or two X1 groups together form a cyclic substituent on the nitrogen atom, or X1 is SO2CH3 when X2 is OX1, or N(X1)2 is NHCOalk

Abstract: Methods and compositions related to the synthesis of photosensitizers of titanium dioxide performed in situ, stepwise, in the solid state, and directly on the surface of the titanium dioxide semiconductor material. The method is generally accomplished by first absorbing an anchor ligand onto the titanium dioxide semiconductor material, then adding an appropriate transition metal, and finally adding one or more secondary ligands to complete the synthesis of the transition metal complex or sensitizer.

Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract: Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3–C6)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted ?-naphthyl, bicyclic heterocyclic aryl, (C3–C6)cycloalkyl-monocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.

Abstract: Provided is a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.

Abstract: Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

Abstract: The present invention concerns a process for arylating or vinylating or alkynating a nucleophilic compound. More particularly, the invention concerns arylating nitrogen-containing organic derivatives. The arylating or vinylating or alkynating process of the invention consists of reacting a nucleophilic compound with a compound carrying a leaving group and is characterized in that the reaction is carried out in the presence of an effective quantity of a catalyst based on a metallic element M selected from groups (VIII), (Ib) and (IIb) of the periodic table and at least one ligand comprising at least one imine function and at least one supplemental nitrogen atom as the chelating atoms.

Abstract: A process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)benzamidine, the process comprising: (a) condensing an optionally suitably substituted diaminobenzene with 2-[4-(1,2,4-oxadiazol-5-on-3-yl)phenylamino]acetic acid; (b) hydrogenating the product obtained from step (a); and (c) optionally carboxylating the amidino group of the product obtained from step (b).

Abstract: The present invention relates to a process for preparing 3,4-dialkoxythiophenes or 3,4-alkylenedioxythiophenes in high yield via the rapid decarboxylation of 3,4-dialkoxythiophenedicarboxylic acid or 3,4-aklylenedioxythiophenedicarboxylic acid in a water-miscible polar solvent in the presence of copper catalyst under an oxygen atmosphere.

Abstract: A method is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel from 9-dihydro-13-acetylbaccatin III. The preparation of a suitably protected baccatin III backbone from 9-dihydro-13-acetylbaccatin III, and the insertion of the phenylisoserine side chain onto the protected baccatin III from 9-dihydro-13-acetylbaccatin III to form the taxane derivatives, paclitaxel and docetaxel is disclosed.

Abstract: The present invention relates to the synthesis of chiral epoxides via a catalytic asymmetric oxidation of olefins. Additionally, the methodology provides a method of asymmetrically oxidizing sulfides and phosphines. This asymmetric oxidation employs a catalyst system composed of a metal and a chiral bishydroxamic acid ligand, which, in the presence of a stoichiometric oxidation reagent, serves to asymmetrically oxidize a variety of substrates.

Abstract: The invention relates to a process for recovering sterols and/or wax alcohols from a crude tall oil based source material comprising sterols and/or wax alcohols in esterified form and fatty and/or rosin acids and optionally sterols and/or wax alcohols in free form, said method comprising the steps of: a) converting free acids in the source material to corresponding salts, b) removing water if present, c) transesterifying the esterified sterols and/or wax alcohols present in the dry material obtained in step a or step b to liberate sterols and/or wax alcohols, d) evaporative fractionating the transesterified material, and e) isolating sterols and/or wax alcohols from the obtained fraction(s) and/or the residue.

Abstract: Monocyclopentadienyl complexes in which the cyclopentadienyl system bears at least one uncharged donor bound via a boron-containing bridge and comprising one or more atoms of group 15 and/or 16 of the Periodic Table of the Elements and is bound to a metal selected from the group consisting of titanium in the oxidation state 3, vanadium, chromium, molybdenum and tungsten, a catalyst system comprising at least one of the monocyclopentadienyl complexes, the use of the catalyst system for the polymerization or copolymerization of olefins and a process for preparing polyolefins by polymerization or copolymerization of olefins in the presence of the catalyst system and polymers obtainable in this way.

Abstract: A metal complex contains at least one ligand, each having the form of a molecule of a fullerene derivative or an anion of the fullerene derivative, where the fullerene derivative, with a solubility in n-hexane of not lower that 0.1 mg/ml at 250° C., includes a fullerene skeleton and three or more organic groups attached to the fullerene skeleton, where each of the organic groups is represented by the general formula (III): —CH2—X(R2)(R3)(R4) ??(III) where X represents an element belonging to the group 14 in the periodic table; and R2, R3 and R4 may be the same or different and each represents a hydrogen atom, hydrocarbon group, alkoxy group or amino group.

Abstract: Bissilylamino group-bearing chlorosilane compounds of formula (1): [(CH3)3Si]2NCH2CH2CH2Si(CH3)nCl3?n ??(1) wherein n is 0 or 1 are novel. They are useful as silane coupling agents and surface treating agents. They can be readily converted, through reaction with alcohols, to bissilyl group-bearing alkoxysilane compounds which are useful as intermediates for the synthesis of aminopropyl-modified silicone oil. The invention also provides an industrially advantageous method capable of preparing the bissilylamino group-bearing chlorosilane compounds.

Abstract: The present invention is related to a method of producing polycarbosilane by heating polydimethylsilane at low pressure within the range of 320˜450° C. using zeolite having the Si/Al or Si/B ratio of 1˜200 as catalyst. This invention uses a zeolite with the structure of ZSM-5, ZSM-11, ZSM-12, zeolite X and zeolite Y, which has the Si/Al or Si/B ratio of 1˜200, as catalyst. When polycarbosilane is produced using a specific zeolite as catalyst, Si/Al or Si/B ratio can be adjusted at any proportion, enabling acidity control of catalyst, and therefore the molecular weight of final products can be easily controlled and the product yield can be improved, compared to conventional solid acid catalysts.

Abstract: The present invention relates to a method of saturating ethylene-containing gases with acetic acid before they are fed into a vinyl acetate reactor, in which the acetic acid recovered in the vinyl acetate process is introduced into a column having a countercurrent stripping section and a rectification section and ethylene-containing gas is supplied via the bottom, wherein the liquid taken off at the bottom of the column is divided into two substreams and one substream is pumped back into the column with maintenance of a minimum pumped circulation required for sufficient saturation with acetic acid.

Abstract: The present invention relates to a process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate, in which 4-(2-nitrophenyl)-n-butyronitrile is converted to 4-(2-nitrophenyl)-n-butyric acid.

Abstract: The present invention relates to a process for the preparation of bis(perfluoroalkyl)phosphinic acids comprising at least the reaction of at least one difluorotris(perfluoroalkyl)phosphorane or at least one trifluorobis(perfluoroalkyl)phosphorane with hydrogen fluoride in a suitable reaction medium, and heating of the resultant reaction mixture. The invention also relates to salts of bis(perfluoroalkyl)phosphinic acids and to the use thereof.

Abstract: In a method of producing pyromellitic acid by liquid-phase oxidizing 2,4,5-trimethylbenzaldehyde in a water solvent with molecular oxygen, a recrystallization mother liquor separated in a recrystallization step is recycled to the oxidation step after a part of the water solvent is removed. With this method, the loss of pyromellitic acid and the oxidation catalyst can be minimized and the burden of discharging the waste water is reduced without lowering the efficiency of the liquid-phase oxidation reaction.

Abstract: This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.

Abstract: A process for the production of acetic acid which comprises carbonylating methanol and/or a reactive derivative thereof in one or more reactors in a liquid reaction composition comprising iridium carbonylation catalyst, ruthenium promoter, methyl iodide co-catalyst, methyl acetate, acetic acid and water. The liquid reaction composition from the one or more reactors is passed to one or more flash separation stages to form (i) a vapor fraction comprising condensable components and a low pressure off-gas comprising carbon monoxide and (ii) a liquid fraction comprising iridium carbonylation catalyst, ruthenium promoter and acetic acid solvent. The condensable components are separated from the low pressure off-gas. The concentration of carbon monoxide in the low pressure off-gas is maintained according to the formula: Y>mX+C wherein Y is the molar concentration of carbon monoxide in the low pressure off-gas, X is the concentration in ppm by weight of ruthenium in the liquid reaction composition, m is about 0.

Abstract: There is described compounds of Formula I, and salts, solvates and hydrates thereof: wherein: R1, R2 and R3 are each independently selected from OH, C1-6alkyl, OC1-6alkyl, OC(O)C1-6alkyl, C(O)OC1-6alkyl, NH2, NH—C1-6alkyl, N(C1-6alkyl)(C1-6alkyl), C(O)NHC1-6alkyl, C(O)N(C1-6alkyl)(C1-6alkyl), SH, SC1-6alkyl, NO2, CF3, OCF3 and halogen; and Ar is an aromatic or heteroaromatic group chosen from benzene, naphthalene, quinoline, isoquinoline, indole, pyridine, pyrasine, pyrimidine, imidazole, furan and thiophene, unsubstituted or substituted with 1–4 substituents independently selected from OH, C1-6alkyl, C1-6alkoxy, C1-3alkylenedioxy, NH2, NH—C1-6alkyl, N(C1-6alkyl)(C1-6)(C1-6alkyl), SH, S—C1-6alkyl, NO2, CF3, OCF3 and halogen. The compounds of Formula I are useful: in therapeutic methods and compositions for modulating cell proliferation, in diagnostic assays and as research tools.

Abstract: The present invention relates to a process for producing 5-nitro-3,4-dihydro-1(2H)-naphthalinone, 1,5-naphthalenediamine and 1,5-naphthalene diisocyanate, in which 4-(2-nitrophenyl)-n-butyronitrile is converted to 4-(2-nitrophenyl)-n-butyric acid.

Abstract: The present invention relates to a process for the alkoxylation of a monool with at least one alkoxylating agent to an alkoxylated alcohol wherein a catalyst is employed which comprises a metallo-organic framework material of metal ions and at least bidentate coordinately bound organic ligands.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF3)2CHOCH2Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF3)2CHOCH2F.

Abstract: A process for producing dimethyl ether, which includes dehydrating methanol in vapor phase in the presence of an activated alumina catalyst having an average pore radius of 2.5 nm to 8.0 nm both inclusive and having a sodium oxide content of 0.07 wt % or less. This invention provides a process for producing DME with an improved conversion ratio using a highly active DME-production catalyst.

Abstract: Processes for preparing fluoroarenes are provided. The processes include contacting a compound having an unactivated aryl group with a source of fluoride or bifluoride in the presence of a transition metal a ligand.

Abstract: A process for the pyrolysis of carbonaceous material is carried out in a cyclone reactor which is fitted with enhanced filtering equipment. In addition the invention relates to the use of a cyclone fitted with a rotating filter as a pyrolysis reactor. By using a cyclone of the rotating separator type as a pyrolysis reactor, carbonaceous material, such as biomass, can effectively be converted in a product having excellent chemical properties and which product is free from particulate matter.

Abstract: This invention related to an improved process for preparation of cumene. More particularly, the present invention relates to a process for the preparation of cumene using catalytic membrane reactors. The membrane used in the process facilitates reaction in a forward direction such that byproduct formation is reduced or eliminated.

Abstract: According to the present invention, there is provided a process for inhibiting the polymerization of an aromatic vinyl compound which is capable of efficiently inhibiting the polymerization of an aromatic vinyl compound not only in an initial stage but also over a long term in the stage of producing, purifying, storing or transporting the aromatic vinyl compound, and which is excellent in handling. The present invention relates to a process for inhibiting the polymerization of an aromatic vinyl compound which requires the step of adding a 2-nitrophenol compound in combination with a sulfonic acid compound to the aromatic vinyl monomer during the stage of producing, purifying, storing or transporting the aromatic vinyl compound.

Abstract: The invention features methods of evaluating the effect of a plurality of different treatments or compounds on a tissue. The method includes providing a tissue from an animal; contacting the tissue with a plurality of treatment, forming on the tissue an array of a plurality of regions or addresses. The method includes the use of a two dimensional array member to contact the plurality of treatments with the tissue and/or to evaluate their effect. The methods are useful for screening large numbers of therapeutic or cosmetic compounds.

Abstract: The present invention relates to a Type II diabetes model mouse, having a causative gene responsible for the following characteristics (1) to (3) in the heterologous or homologous state, wherein the characteristics are autosomal recessive genetic traits: (1) having a higher blood sugar level as compared to a normal strain mouse at 10 to 14 weeks of age and having a blood glycosylated hemoglobin concentration of 2.5% or higher at 10 to 14 weeks of age or older; (2) being positive in test for urine sugar at 10 to 14 weeks of age; and (3) exhibiting essentially no inflammation of the pancreatic islets and having a blood insulin concentration equivalent to or higher than that of a normal strain mouse. According to the present invention, there is provided a novel mouse having a gene responsible for the spontaneous development of type II diabetes.

Abstract: The present application provides a human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D2 synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D2 synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene. The present application also provides a method of using the transgenic animal for testing in vivo activity of a candidate for anti-allergy medicines, sleep-controlling substances and candidates for anti-obesity.